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Background: Antimicrobial therapy is essential for the treatment of enteric fever, the infection caused by
Salmonella serovars Typhi and Paratyphi A. However, an increase in resistance to key antimicrobials and the
emergence of MDR and XDR in Salmonella Typhi poses a major threat for efficacious outpatient treatments.
Objectives: We recently identified tebipenem, an oral carbapenem licensed for use for respiratory tract infec-
tions in Japan, as a potential alternative treatment for MDR/XDR Shigella spp. Here, we aimed to test the in vitro
antibacterial efficacy of this drug against MDR and XDR typhoidal Salmonella.
Methods: We determined the in vitro activity of tebipenem in time–kill assays against a collection of non-XDR
and XDR Salmonella Typhi and Salmonella Paratyphi A (non-XDR) isolated in Nepal and Bangladesh. We also
tested the efficacy of tebipenem in combination with other antimicrobials.
Results: We found that both XDR and non-XDR Salmonella Typhi and Salmonella Paratyphi A are susceptible to
tebipenem, exhibiting low MICs, and were killed within 8–24 h at 2–4%MIC. Additionally, tebipenem demon-
strated synergy with two other antimicrobials and could efficiently induce bacterial killing.
Conclusions: Salmonella Paratyphi A and XDR Salmonella Typhi display in vitro susceptibility to the oral carbape-
nem tebipenem, while synergistic activity with other antimicrobials may limit the emergence of resistance. The
broad-spectrum activity of this drug against MDR/XDR organisms renders tebipenem a good candidate for clinical
trials.
Introduction
Antimicrobial resistance poses a major threat for enteric (typhoid)
fever treatment, as well as infections caused by other Gram-
negative bacteria, such as Shigella spp. and pathogenic Escherichia
coli.1 Enteric fever is a life-threatening systemic disease caused by
Salmonella enterica serovar Typhi and the various pathovars of
Salmonella Paratyphi (A, B and C). Enteric fever remains a public
health problem in many countries in South Asia and sub-Saharan
Africa with poor sanitation, resulting in an estimated global inci-
dence of >14 million cases and >135 000 deaths annually.2
MDR Salmonella Typhi (resistant to ampicillin, chloramphenicol
and trimethoprim/sulfamethoxazole) have become common and
been facilitated by the global expansion of the H58 lineage.3 More
recently, XDR Salmonella Typhi, characterized by resistance to fluo-
roquinolones and third-generation cephalosporins in combination
with the standard MDR phenotype, have been isolated in
Pakistan.4 XDR Salmonella Typhi have since been identified in other
countries and been associated with travel to Pakistan.5 Alarmingly,
cases of XDR typhoid (identical susceptibility profile to isolates
from Pakistan) with no recent travel history have recently been
recorded in the USA.6
XDR Salmonella Typhi isolates remain largely susceptible to
azithromycin and carbapenems,4,7 with guidelines in Pakistan and
the American CDC recommending these antimicrobials as mono-
therapy or in combination for the treatment of XDR typhoid
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infections.6 However, azithromycin resistance has been recorded
in both Salmonella Typhi and Salmonella Paratyphi A and appears
to be increasing.8 The carbapenems are a potent class of b-lactam
antimicrobials used to treat life-threatening bacterial infections
and XDR typhoid can be effectively treated by meropenem or imi-
penem. Unfortunately, these antimicrobials are administered par-
enterally, thus largely restricting their use to inpatients.
Our repertoire of oral antimicrobials against MDR/XDR organ-
isms is becoming limited and the emergence of XDR Salmonella
Typhi highlights the need for alternative antimicrobials to treat
infections associated with these highly resistant organisms. We re-
cently identified tebipenem as a drug-repurposing opportunity for
infections caused by MDR Shigella, for clinical Shigella isolates
exhibiting MIC values of 0.02–0.15 mg/L.9 The prodrug, tebipenem
pivoxil, is an oral carbapenem that is only licensed for use in paedi-
atric patients with serious respiratory infections in Japan.10 It
presents with high oral bioavailability, a broad spectrum and acti-
vation in gut enterocytes, potentially offering a solution for treat-
ing XDR infections without the requirement for hospitalization.
Spero Therapeutics is developing an adult formulation with an
extended half-life.10 The reported breakpoints for tebipenem activ-
ity against other Gram-negative bacteria, such as Haemophilus in-
fluenza and Escherichia coli, propose that tebipenem-susceptible
bacteria have MIC values <1 mg/L.10,11 Here, we aimed to under-
stand the potential of tebipenem as a new oral therapeutic to treat
typhoid fever caused by XDR Salmonella Typhi.
Materials and methods
The Salmonella Typhi and Salmonella Paratyphi A organisms used in this
study were previously isolated in Nepal (n = 21; non-MDR/non-XDR)12 and in
Pakistan (n = 79; all XDR).4 Bacteria were cultured in Mueller–Hinton (MH)
medium (Sigma–Aldrich, UK) overnight at 37C. The MIC values of tebipe-
nem (Sigma–Aldrich, UK) were determined by an existing microdilution
assay.9 Briefly, 10lM tebipenem in MH broth was serially diluted and
5%105 cfu/mL bacteria were added and incubated at 37C overnight in a
total volume of 200 lL. Bacterial growth was detected by plating 10lL of
solution from each well on Nutrient Agar (NA; Oxoid) and incubating over-
night at 37C. Results were interpreted as the minimal concentration ne-
cessary to inhibit growth (i.e. no growth visible in the 10lL aliquot).
Time–kill curve assays were performed in 50 mL Falcon tubes by cultur-
ing Salmonella in MH medium in the presence of four antimicrobial concen-
trations in doubling dilutions ranging from 0.5%MIC to 4%MIC. Bacterial
stocks were prepared in 0.9% NaCl and added to each tube to obtain a con-
centration of 5%105 cfu/mL. Bacteria were grown with agitation at
200 rpm at 37C and monitored over a time course of 24 h (0, 2, 4, 6, 8 and
24 h). For every concentration and timepoint, bacterial cultures were
diluted and inoculated onto NA, before being incubated at 37C overnight
and cfu were enumerated.
Combination studies with clinical isolates were performed as previously
described.9 MICs were determined for drug A and drug B alone and in com-
bination. The MIC of each drug in the combination was expressed as the
fraction of the MIC of the drug alone normalized to 1, representing the frac-
tional inhibitory concentration (FIC), with the sum of the FICs [(MIC of drug
A in combination/MIC of drug A alone)!(MIC of drug B in combination/MIC
of drug B alone)] giving the FIC index (FICI) score.
Figure 1. Tebipenem as an oral alternative for the treatment of enteric fever caused by MDR/XDR Salmonella Typhi/Salmonella Paratyphi A. (a)
Tukey boxplots showing MIC values of tebipenem for Salmonella Typhi (STY) and Salmonella Paratyphi A (SPA) isolated from Pakistan and Nepal.
The isolates from Pakistan are all XDR STY. (b) Tebipenem MIC and MBC values for STY 01TY257 and SPA 02TY224. Representative time–kill curves
of STY (c) and SPA (d) isolates in various doubling concentrations of tebipenem compared with bacteria grown with no treatment (NT). (e) Bar chart
showing the average FICI scores to determine the in vitro synergy or antagonism of tebipenem (TP) in combination with an LpxC inhibitor (PF;
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Results
To determine the repurposing potential of tebipenem for typhoidal
Salmonella, we measured the inhibitory activity of this compound
against a collection of 100 clinical non-XDR and XDR Salmonella
Typhi and non-XDR Salmonella Paratyphi A from Pakistan and
Nepal. The MIC values of tebipenem for tested isolates were con-
sistently 0.62 mg/L (IQR = 0.12–0.25 mg/L; Figure 1a), even for
the XDR isolates. The majority of Salmonella Typhi from both
Pakistan (XDR) and Nepal (non-XDR) had lower MIC values
(median = 0.12 mg/L and 0.039 mg/L, respectively) compared with
Nepali Salmonella Paratyphi A (non-XDR) (median = 0.31 mg/L);
the latter also included the least tebipenem-susceptible isolates in
our collection (ED199, 02TY067, DM188 and ED293 with MICs of
0.62 mg/L). These data suggest that the drug is likely to work in en-
teric fever patients infected with XDR and non-XDR isolates.
Identifying that all organisms were susceptible to tebipenem,
we selected two isolates (Salmonella Typhi 01TY257 and
Salmonella Paratyphi A 02TY224) to further investigate the bacteri-
cidal effect of tebipenem on typhoidal Salmonella. The tebipenem
MIC and MBC values for Salmonella Paratyphi A 02TY224 were 4
and 8 times higher, respectively, compared with those for
Salmonella Typhi 01TY257 (Figure 1b). Time–kill assays of tebipe-
nem showed that the compound exhibited high-level bactericidal
activity against both isolates, with rapid killing occurring during the
first 6 h of exposure (Figure 1c and d). Salmonella Typhi 01TY257
was effectively killed by tebipenem at 2%MIC after 24 h and at
4%MIC within 8 h (Figure 1c). In comparison, tebipenem induced
complete killing of Salmonella Paratyphi A 02TY224 at 4%MIC only
after 24 h of exposure (Figure 1d). Notably, both Salmonella Typhi
and Salmonella Paratyphi A recovered growth when treated with
0.5–1%MIC after 6–8 h of tebipenem exposure (Figure 1c and d).
We next determined the synergistic abilities of tebipenem com-
bined with azithromycin and an LpxC inhibitor (PF-5081090) in
in vitro assays. Azithromycin often remains the last-available anti-
microbial for treating uncomplicated enteric fever,13,14 while we
have found that LpxC inhibitors show synergy with tepibenem and
retain activity against Shigella clinical isolates.9 Tebipenem com-
bined with either the LpxC inhibitor or azithromycin resulted in par-
tial synergy (FICI scores of 0.5) for both tested Salmonella Typhi
and Salmonella Paratyphi A isolates (Figure 1e) and notably even
for azithromycin-resistant Salmonella Paratyphi A.
Discussion
Carbapenems remain the last-resort treatment for many infec-
tions and thus the emergence of resistance must be mitigated.
However, carbapenem resistance is not uncommon15 and many
bacterial pathogens causing nosocomial infections, such as
Klebsiella pneumoniae, employ resistance mechanisms, such as
plasmid-borne carbapenemases and/or the modification of outer
membrane influx proteins.16,17 Combining tebipenem with other
commonly used antimicrobials with different modes of action may
restore and/or increase the efficacy of both antimicrobials in a com-
bination against MDR/XDR pathogens and may prove to be effective
in reducing the risk of developing resistance to carbapenems.9
These results suggest that these combinations may be benefi-
cial to protect the efficiency of tebipenem and limit the emergence
of resistance to this vital class of antimicrobials. Indeed, studies
with other antmicrobials targeting Gram-negative bacteria have
indicated that combination therapy shows better efficacy, lower
mortality, higher recovery and lower rates of resistance compared
with monotherapy.18 Given the high in vitro potency of tebipenem
against a range of enteric pathogens and the prodrug hydrolysis
and active-ingredient release within enterocytes, we suggest it
could be administered before obtaining culture results when XDR
typhoid is considered.9 Tebipenem is already licensed in Japan
(Orapenem) to treat paediatric respiratory infections and has exist-
ing safety documentation,10 rendering it an attractive compound
for clinical trials of MDR/XDR typhoidal Salmonella.
We are in urgent need of new antimicrobials for the treatment
of infections caused by XDR organisms and the emergence of XDR
typhoid in Pakistan and the USA has left azithromycin as the only
remaining oral alternative. Our data show that Orapenem (tebipe-
nem pivoxil) may offer some respite in the community treatment
of XDR enteric fever and that resistance may be prevented by com-
bining this carbapenem with an antimicrobial with an alternative
mode of action.
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